Scleral Plaques in Nephrogenic Systemic Fibrosis

Article Type
Changed
Wed, 02/02/2022 - 16:25
Display Headline
Scleral Plaques in Nephrogenic Systemic Fibrosis

To the Editor:

A 44-year-old man with a history of systemic lupus erythematosus (SLE) complicated by lupus nephritis, end-stage renal disease, and antiphospholipid syndrome was evaluated for progressive skin tightening over the last 3 years, predominantly on the hands but also involving the feet, legs, and arms. Physical examination revealed multiple flesh-colored to hypopigmented, bound-down, indurated, fissured plaques over the distal upper and lower extremities, most prominent over the hands (Figure 1). Yellow plaques appeared on the lateral sclera of both eyes (Figure 2). A diagnosis of nephrogenic systemic fibrosis (NSF) was supported by typical findings on punch biopsy, including a proliferation of dermal fibroblasts with thickened collagen bundles and mucin deposition.

Bound-down, indurated, fissured plaques most prominent on the hands in a patient with nephrogenic systemic fibrosis.
FIGURE 1. A and B, Bound-down, indurated, fissured plaques most prominent on the hands in a patient with nephrogenic systemic fibrosis.

Nephrogenic systemic fibrosis, also known as nephrogenic fibrosing dermopathy, is characterized by fibrotic plaques and nodules that tend to be bilateral.1 The chronic course of this disease often is accompanied by flexion contractures. Yellow scleral plaques caused by calcium phosphate deposition are present in up to 75% of cases and are more specific to a diagnosis of NSF in patients younger than 45 years.1,2 A strong association exists between NSF and gadolinium contrast agents in patients with acute renal failure; our patient later confirmed multiple gadolinium exposures years prior. Deposits of gadolinium have even been found in NSF skin lesions.2

A yellow plaque was noted on the lateral sclera in a patient with nephrogenic systemic fibrosis.
FIGURE 2. A yellow plaque was noted on the lateral sclera in a patient with nephrogenic systemic fibrosis.

References
  1. Stone JH. A Clinician’s Pearls & Myths in Rheumatology. Springer London; 2009.
  2. Barker-Griffith A, Goldberg J, Abraham JL. Ocular pathologic features and gadolinium deposition in nephrogenic systemic fibrosis. Arch Ophthalmol. 2011;129:661-663.
Article PDF
Author and Disclosure Information

All were from the Division of Dermatology, University of California Los Angeles. Dr. Dreyer currently is from the Department of Physical Medicine and Rehabilitation, Northwestern Medical Center, Chicago, Illinois. Dr. Rodriguez currently is from Health Partners Park Nicollet, Burnsville, Minnesota. Dr. Worswick currently is from the Department of Dermatology, Keck Medicine of USC, Los Angeles, California.

The authors report no conflict of interest.

Correspondence: Scott Worswick, MD, 1450 San Pablo St, Los Angeles, CA 90033 (scott.worswick@gmail.com).

Issue
Cutis - 109(1)
Publications
Topics
Page Number
E31-E32
Sections
Author and Disclosure Information

All were from the Division of Dermatology, University of California Los Angeles. Dr. Dreyer currently is from the Department of Physical Medicine and Rehabilitation, Northwestern Medical Center, Chicago, Illinois. Dr. Rodriguez currently is from Health Partners Park Nicollet, Burnsville, Minnesota. Dr. Worswick currently is from the Department of Dermatology, Keck Medicine of USC, Los Angeles, California.

The authors report no conflict of interest.

Correspondence: Scott Worswick, MD, 1450 San Pablo St, Los Angeles, CA 90033 (scott.worswick@gmail.com).

Author and Disclosure Information

All were from the Division of Dermatology, University of California Los Angeles. Dr. Dreyer currently is from the Department of Physical Medicine and Rehabilitation, Northwestern Medical Center, Chicago, Illinois. Dr. Rodriguez currently is from Health Partners Park Nicollet, Burnsville, Minnesota. Dr. Worswick currently is from the Department of Dermatology, Keck Medicine of USC, Los Angeles, California.

The authors report no conflict of interest.

Correspondence: Scott Worswick, MD, 1450 San Pablo St, Los Angeles, CA 90033 (scott.worswick@gmail.com).

Article PDF
Article PDF

To the Editor:

A 44-year-old man with a history of systemic lupus erythematosus (SLE) complicated by lupus nephritis, end-stage renal disease, and antiphospholipid syndrome was evaluated for progressive skin tightening over the last 3 years, predominantly on the hands but also involving the feet, legs, and arms. Physical examination revealed multiple flesh-colored to hypopigmented, bound-down, indurated, fissured plaques over the distal upper and lower extremities, most prominent over the hands (Figure 1). Yellow plaques appeared on the lateral sclera of both eyes (Figure 2). A diagnosis of nephrogenic systemic fibrosis (NSF) was supported by typical findings on punch biopsy, including a proliferation of dermal fibroblasts with thickened collagen bundles and mucin deposition.

Bound-down, indurated, fissured plaques most prominent on the hands in a patient with nephrogenic systemic fibrosis.
FIGURE 1. A and B, Bound-down, indurated, fissured plaques most prominent on the hands in a patient with nephrogenic systemic fibrosis.

Nephrogenic systemic fibrosis, also known as nephrogenic fibrosing dermopathy, is characterized by fibrotic plaques and nodules that tend to be bilateral.1 The chronic course of this disease often is accompanied by flexion contractures. Yellow scleral plaques caused by calcium phosphate deposition are present in up to 75% of cases and are more specific to a diagnosis of NSF in patients younger than 45 years.1,2 A strong association exists between NSF and gadolinium contrast agents in patients with acute renal failure; our patient later confirmed multiple gadolinium exposures years prior. Deposits of gadolinium have even been found in NSF skin lesions.2

A yellow plaque was noted on the lateral sclera in a patient with nephrogenic systemic fibrosis.
FIGURE 2. A yellow plaque was noted on the lateral sclera in a patient with nephrogenic systemic fibrosis.

To the Editor:

A 44-year-old man with a history of systemic lupus erythematosus (SLE) complicated by lupus nephritis, end-stage renal disease, and antiphospholipid syndrome was evaluated for progressive skin tightening over the last 3 years, predominantly on the hands but also involving the feet, legs, and arms. Physical examination revealed multiple flesh-colored to hypopigmented, bound-down, indurated, fissured plaques over the distal upper and lower extremities, most prominent over the hands (Figure 1). Yellow plaques appeared on the lateral sclera of both eyes (Figure 2). A diagnosis of nephrogenic systemic fibrosis (NSF) was supported by typical findings on punch biopsy, including a proliferation of dermal fibroblasts with thickened collagen bundles and mucin deposition.

Bound-down, indurated, fissured plaques most prominent on the hands in a patient with nephrogenic systemic fibrosis.
FIGURE 1. A and B, Bound-down, indurated, fissured plaques most prominent on the hands in a patient with nephrogenic systemic fibrosis.

Nephrogenic systemic fibrosis, also known as nephrogenic fibrosing dermopathy, is characterized by fibrotic plaques and nodules that tend to be bilateral.1 The chronic course of this disease often is accompanied by flexion contractures. Yellow scleral plaques caused by calcium phosphate deposition are present in up to 75% of cases and are more specific to a diagnosis of NSF in patients younger than 45 years.1,2 A strong association exists between NSF and gadolinium contrast agents in patients with acute renal failure; our patient later confirmed multiple gadolinium exposures years prior. Deposits of gadolinium have even been found in NSF skin lesions.2

A yellow plaque was noted on the lateral sclera in a patient with nephrogenic systemic fibrosis.
FIGURE 2. A yellow plaque was noted on the lateral sclera in a patient with nephrogenic systemic fibrosis.

References
  1. Stone JH. A Clinician’s Pearls & Myths in Rheumatology. Springer London; 2009.
  2. Barker-Griffith A, Goldberg J, Abraham JL. Ocular pathologic features and gadolinium deposition in nephrogenic systemic fibrosis. Arch Ophthalmol. 2011;129:661-663.
References
  1. Stone JH. A Clinician’s Pearls & Myths in Rheumatology. Springer London; 2009.
  2. Barker-Griffith A, Goldberg J, Abraham JL. Ocular pathologic features and gadolinium deposition in nephrogenic systemic fibrosis. Arch Ophthalmol. 2011;129:661-663.
Issue
Cutis - 109(1)
Issue
Cutis - 109(1)
Page Number
E31-E32
Page Number
E31-E32
Publications
Publications
Topics
Article Type
Display Headline
Scleral Plaques in Nephrogenic Systemic Fibrosis
Display Headline
Scleral Plaques in Nephrogenic Systemic Fibrosis
Sections
Inside the Article

Practice Points

  • It is important to examine the eyes in a patient with sclerotic skin changes on physical examination.
  • The presence of yellow scleral plaques strongly is associated with a diagnosis of nephrogenic systemic fibrosis.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Article PDF Media

Lichen Planopilaris in a Patient Treated With Bexarotene for Lymphomatoid Papulosis

Article Type
Changed
Tue, 04/28/2020 - 11:28
Display Headline
Lichen Planopilaris in a Patient Treated With Bexarotene for Lymphomatoid Papulosis

To the Editor:

Lymphomatoid papulosis is a rare chronic skin disorder characterized by recurrent, self-healing crops of papulonodular eruptions, often resembling cutaneous T-cell lymphoma.1 Oral bexarotene, a retinoid X receptor–selective retinoid, can be used to control the disease.2,3 Lichen planopilaris (LPP) is a type of cicatricial alopecia characterized by irreversible hair loss, perifollicular inflammation, and follicular hyperkeratosis, commonly affecting the scalp vertex in adults.4 We report a case of a patient with lymphomatoid papulosis who was treated with bexarotene and subsequently developed LPP. We also discuss a proposed mechanism by which bexarotene may have influenced the onset of LPP.

A 35-year-old woman who was previously healthy initially presented with recurrent pruritic papular eruptions on the flank, axillae, and groin of several months’ duration. The lesions appeared as 2-mm, flat-topped, violaceous papules. The patient had no known drug allergies, no medical or family history of skin disease, and was only taking 3000 mg/d of omega-3 fatty acids (fish oil). Histopathologic examination of a biopsy specimen from the inner thigh showed enlarged, atypical, dermal lymphocytes that were CD30+ (Figure 1). These findings were consistent with lymphomatoid papulosis. As she had undergone tubal ligation several years prior, she was prescribed oral bexarotene 300 mg once daily in addition to triamcinolone cream 0.1% twice daily, as needed. Symptoms were well controlled on this regimen.

Figure 1. Histologic findings from a biopsy of the inner thigh. A, A superficial and deep, wedge-shaped lymphoid infiltrate was observed in the dermis (H&E, original magnification ×40). B, Highpower view showed a mixture of enlarged atypical lymphoid cells admixed with lymphocytes, histiocytes, and eosinophils (H&E, original magnification ×400). C, CD30 immunohistochemical stain highlighted an increase in CD30+ lymphoid cells arranged singly and in clusters (original magnification ×200).


Six months later the patient returned, presenting with a new central patch of scarring alopecia on the vertex of the scalp (Figure 2). Adjacent to the area of hair loss were areas of prominent perifollicular scale that were slightly violaceous in color. Two 4-mm punch biopsies of the scalp showed dermal scarring with perifollicular lamellar fibrosis surrounded by a rim of lymphoplasmacytic inflammation (Figure 3). Sebaceous glands were found to be reduced in number. These findings were consistent with cicatricial alopecia, which was further classified as LPP in conjunction with the clinical findings. No CD30+ lymphocytes were identified in these specimens.

Figure 2. Patch of scarring alopecia with perifollicular erythema.

Figure 3. Histologic findings from a biopsy of the vertex of the scalp. A, Vertical section showed dermal fibrosis and perifollicular chronic inflammation (H&E, original magnification ×40). B, Horizontal section showed follicular dropout, perifollicular fibrosis, and perifollicular lichenoid inflammation (H&E, original magnification ×40).

Baseline fasting triglycerides were 123 mg/dL (desirable: <150 mg/dL; borderline: 150–199 mg/dL; high: ≥200 mg/dL) and were stable over the first 4 months on bexarotene. After 5 months of therapy, the triglycerides increased to a high of 255 mg/dL, which corresponded with the onset of LPP. She was treated for the hypertriglyceridemia with omega-3 fatty acids (fish oil), and subsequent triglyceride levels have normalized and been stable. Her alopecia has not progressed but is persistent. She continues to have central hypothyroidism due to bexarotene and is on levothyroxine. The lymphomatoid papulosis also remains stable with no signs of progression to cutaneous T-cell lymphoma.

Although the exact mechanism of LPP is not fully understood, studies have suggested that cellular lipid metabolism may be responsible for the inflammation of the pilosebaceous unit.4-11 Hyperlipidemia is the most common side effect of oral bexarotene, typically occurring within the first 2 to 4 weeks of treatment.3,12 Considering the insights into the role of lipid regulation on LPP pathogenesis, it is reasonable to suspect that the dyslipidemia caused by bexarotene may have triggered the onset of LPP in our patient. The patient’s lipid values mostly remained within reference range throughout the course of treatment, though she did have elevation of triglycerides around the onset of LPP. Dyslipidemia has been reported in patients with lichen planus but not in patients with LPP. One case-control study showed no dyslipidemia in patients with LPP, but the triglyceride levels were not tracked over time and patients had varying durations since onset of disease at presentation.9-11,13 In our case, we were fortunate to have this information, and it may suggest an interaction between lipid dysregulation and the development of LPP. It would be interesting to explore this further in a larger patient population and to evaluate if control of dyslipidemia reduces progression of disease as it appears to have done for our patient.

References
  1. Karp DL, Horn TD. Lymphomatoid papulosis. J Am Acad Dermatol. 1994;30:379-395; quiz 396-398.
  2. Krathen RA, Ward S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology. 2003;206:142-147.
  3. Targretin (bexarotene) capsule [package insert]. St. Petersburg, FL: Cardinal Health; 2003. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63656f64-e240-4855-8df9-ca1655863735. Accessed April 9, 2020.
  4. Assouly P, Reygagne P. Lichen planopilaris: update on diagnosis and treatment. Semin Cutan Med Surg. 2009;28:3-10.
  5. Dogra S, Sarangal R. What’s new in cicatricial alopecia? Indian J Dermatol Venereol Leprol. 2013;79:576-90.
  6. Zheng Y, Eilertsen KJ, Ge L, et al. Scd1 is expressed in sebaceous glands and is disrupted in the asebia mouse. Nat Genet. 1999;23:268-270.
  7. Sundberg JP, Boggess D, Sundberg BA, et al. Asebia-2J (Scd1(ab2J)): a new allele and a model for scarring alopecia. Am J Pathol. 2000;156:2067-2075.
  8. Karnik P, Tekeste Z, McCormick TS, et al. Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. J Invest Dermatol. 2009;129:1243-157.
  9. López-Jornet P, Camacho-Alonso F, Rodríguez-Martínes MA. Alterations in serum lipid profile patterns in oral lichen planus: a cross-sectional study. Am J Clin Dermatol. 2012;13:399-404.
  10. Arias-Santiago S, Buendía-Eisman A, Aneiros-Fernández J, et al. Lipid levels in patients with lichen planus: a case-control study. J Eur Acad Dermatol Venereol. 2011;25:1398-1401.
  11. Dreiher J, Shapiro J, Cohen AD. Lichen planus and dyslipidaemia: a case-control study. Br J Dermatol. 2009;161:626-629.
  12. de Vries-van der Weij J, de Haan W, Hu L, et al. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. Endocrinology. 2009;150:2368-2375.
  13. Conic RRZ, Piliang M, Bergfeld W, et al. Association of lichen planopilaris with dyslipidemia. JAMA Dermatol. 2018;154:1088-1089.
Article PDF
Author and Disclosure Information

From the David Geffen School of Medicine, University of California Los Angeles. Dr. Smart is from the Department of Pathology, and Dr. Goh is from the Department of Medicine-Dermatology. Dr. Dreyer currently is from the Department of Physical Medicine and Rehabilitation, Northwestern University, Chicago, Illinois.

The authors report no conflict of interest.

Correspondence: Carolyn Goh, MD, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095 (cgoh@mednet.ucla.edu).

Issue
Cutis - 105(4)
Publications
Topics
Page Number
E19-E21
Sections
Author and Disclosure Information

From the David Geffen School of Medicine, University of California Los Angeles. Dr. Smart is from the Department of Pathology, and Dr. Goh is from the Department of Medicine-Dermatology. Dr. Dreyer currently is from the Department of Physical Medicine and Rehabilitation, Northwestern University, Chicago, Illinois.

The authors report no conflict of interest.

Correspondence: Carolyn Goh, MD, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095 (cgoh@mednet.ucla.edu).

Author and Disclosure Information

From the David Geffen School of Medicine, University of California Los Angeles. Dr. Smart is from the Department of Pathology, and Dr. Goh is from the Department of Medicine-Dermatology. Dr. Dreyer currently is from the Department of Physical Medicine and Rehabilitation, Northwestern University, Chicago, Illinois.

The authors report no conflict of interest.

Correspondence: Carolyn Goh, MD, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095 (cgoh@mednet.ucla.edu).

Article PDF
Article PDF

To the Editor:

Lymphomatoid papulosis is a rare chronic skin disorder characterized by recurrent, self-healing crops of papulonodular eruptions, often resembling cutaneous T-cell lymphoma.1 Oral bexarotene, a retinoid X receptor–selective retinoid, can be used to control the disease.2,3 Lichen planopilaris (LPP) is a type of cicatricial alopecia characterized by irreversible hair loss, perifollicular inflammation, and follicular hyperkeratosis, commonly affecting the scalp vertex in adults.4 We report a case of a patient with lymphomatoid papulosis who was treated with bexarotene and subsequently developed LPP. We also discuss a proposed mechanism by which bexarotene may have influenced the onset of LPP.

A 35-year-old woman who was previously healthy initially presented with recurrent pruritic papular eruptions on the flank, axillae, and groin of several months’ duration. The lesions appeared as 2-mm, flat-topped, violaceous papules. The patient had no known drug allergies, no medical or family history of skin disease, and was only taking 3000 mg/d of omega-3 fatty acids (fish oil). Histopathologic examination of a biopsy specimen from the inner thigh showed enlarged, atypical, dermal lymphocytes that were CD30+ (Figure 1). These findings were consistent with lymphomatoid papulosis. As she had undergone tubal ligation several years prior, she was prescribed oral bexarotene 300 mg once daily in addition to triamcinolone cream 0.1% twice daily, as needed. Symptoms were well controlled on this regimen.

Figure 1. Histologic findings from a biopsy of the inner thigh. A, A superficial and deep, wedge-shaped lymphoid infiltrate was observed in the dermis (H&E, original magnification ×40). B, Highpower view showed a mixture of enlarged atypical lymphoid cells admixed with lymphocytes, histiocytes, and eosinophils (H&E, original magnification ×400). C, CD30 immunohistochemical stain highlighted an increase in CD30+ lymphoid cells arranged singly and in clusters (original magnification ×200).


Six months later the patient returned, presenting with a new central patch of scarring alopecia on the vertex of the scalp (Figure 2). Adjacent to the area of hair loss were areas of prominent perifollicular scale that were slightly violaceous in color. Two 4-mm punch biopsies of the scalp showed dermal scarring with perifollicular lamellar fibrosis surrounded by a rim of lymphoplasmacytic inflammation (Figure 3). Sebaceous glands were found to be reduced in number. These findings were consistent with cicatricial alopecia, which was further classified as LPP in conjunction with the clinical findings. No CD30+ lymphocytes were identified in these specimens.

Figure 2. Patch of scarring alopecia with perifollicular erythema.

Figure 3. Histologic findings from a biopsy of the vertex of the scalp. A, Vertical section showed dermal fibrosis and perifollicular chronic inflammation (H&E, original magnification ×40). B, Horizontal section showed follicular dropout, perifollicular fibrosis, and perifollicular lichenoid inflammation (H&E, original magnification ×40).

Baseline fasting triglycerides were 123 mg/dL (desirable: <150 mg/dL; borderline: 150–199 mg/dL; high: ≥200 mg/dL) and were stable over the first 4 months on bexarotene. After 5 months of therapy, the triglycerides increased to a high of 255 mg/dL, which corresponded with the onset of LPP. She was treated for the hypertriglyceridemia with omega-3 fatty acids (fish oil), and subsequent triglyceride levels have normalized and been stable. Her alopecia has not progressed but is persistent. She continues to have central hypothyroidism due to bexarotene and is on levothyroxine. The lymphomatoid papulosis also remains stable with no signs of progression to cutaneous T-cell lymphoma.

Although the exact mechanism of LPP is not fully understood, studies have suggested that cellular lipid metabolism may be responsible for the inflammation of the pilosebaceous unit.4-11 Hyperlipidemia is the most common side effect of oral bexarotene, typically occurring within the first 2 to 4 weeks of treatment.3,12 Considering the insights into the role of lipid regulation on LPP pathogenesis, it is reasonable to suspect that the dyslipidemia caused by bexarotene may have triggered the onset of LPP in our patient. The patient’s lipid values mostly remained within reference range throughout the course of treatment, though she did have elevation of triglycerides around the onset of LPP. Dyslipidemia has been reported in patients with lichen planus but not in patients with LPP. One case-control study showed no dyslipidemia in patients with LPP, but the triglyceride levels were not tracked over time and patients had varying durations since onset of disease at presentation.9-11,13 In our case, we were fortunate to have this information, and it may suggest an interaction between lipid dysregulation and the development of LPP. It would be interesting to explore this further in a larger patient population and to evaluate if control of dyslipidemia reduces progression of disease as it appears to have done for our patient.

To the Editor:

Lymphomatoid papulosis is a rare chronic skin disorder characterized by recurrent, self-healing crops of papulonodular eruptions, often resembling cutaneous T-cell lymphoma.1 Oral bexarotene, a retinoid X receptor–selective retinoid, can be used to control the disease.2,3 Lichen planopilaris (LPP) is a type of cicatricial alopecia characterized by irreversible hair loss, perifollicular inflammation, and follicular hyperkeratosis, commonly affecting the scalp vertex in adults.4 We report a case of a patient with lymphomatoid papulosis who was treated with bexarotene and subsequently developed LPP. We also discuss a proposed mechanism by which bexarotene may have influenced the onset of LPP.

A 35-year-old woman who was previously healthy initially presented with recurrent pruritic papular eruptions on the flank, axillae, and groin of several months’ duration. The lesions appeared as 2-mm, flat-topped, violaceous papules. The patient had no known drug allergies, no medical or family history of skin disease, and was only taking 3000 mg/d of omega-3 fatty acids (fish oil). Histopathologic examination of a biopsy specimen from the inner thigh showed enlarged, atypical, dermal lymphocytes that were CD30+ (Figure 1). These findings were consistent with lymphomatoid papulosis. As she had undergone tubal ligation several years prior, she was prescribed oral bexarotene 300 mg once daily in addition to triamcinolone cream 0.1% twice daily, as needed. Symptoms were well controlled on this regimen.

Figure 1. Histologic findings from a biopsy of the inner thigh. A, A superficial and deep, wedge-shaped lymphoid infiltrate was observed in the dermis (H&E, original magnification ×40). B, Highpower view showed a mixture of enlarged atypical lymphoid cells admixed with lymphocytes, histiocytes, and eosinophils (H&E, original magnification ×400). C, CD30 immunohistochemical stain highlighted an increase in CD30+ lymphoid cells arranged singly and in clusters (original magnification ×200).


Six months later the patient returned, presenting with a new central patch of scarring alopecia on the vertex of the scalp (Figure 2). Adjacent to the area of hair loss were areas of prominent perifollicular scale that were slightly violaceous in color. Two 4-mm punch biopsies of the scalp showed dermal scarring with perifollicular lamellar fibrosis surrounded by a rim of lymphoplasmacytic inflammation (Figure 3). Sebaceous glands were found to be reduced in number. These findings were consistent with cicatricial alopecia, which was further classified as LPP in conjunction with the clinical findings. No CD30+ lymphocytes were identified in these specimens.

Figure 2. Patch of scarring alopecia with perifollicular erythema.

Figure 3. Histologic findings from a biopsy of the vertex of the scalp. A, Vertical section showed dermal fibrosis and perifollicular chronic inflammation (H&E, original magnification ×40). B, Horizontal section showed follicular dropout, perifollicular fibrosis, and perifollicular lichenoid inflammation (H&E, original magnification ×40).

Baseline fasting triglycerides were 123 mg/dL (desirable: <150 mg/dL; borderline: 150–199 mg/dL; high: ≥200 mg/dL) and were stable over the first 4 months on bexarotene. After 5 months of therapy, the triglycerides increased to a high of 255 mg/dL, which corresponded with the onset of LPP. She was treated for the hypertriglyceridemia with omega-3 fatty acids (fish oil), and subsequent triglyceride levels have normalized and been stable. Her alopecia has not progressed but is persistent. She continues to have central hypothyroidism due to bexarotene and is on levothyroxine. The lymphomatoid papulosis also remains stable with no signs of progression to cutaneous T-cell lymphoma.

Although the exact mechanism of LPP is not fully understood, studies have suggested that cellular lipid metabolism may be responsible for the inflammation of the pilosebaceous unit.4-11 Hyperlipidemia is the most common side effect of oral bexarotene, typically occurring within the first 2 to 4 weeks of treatment.3,12 Considering the insights into the role of lipid regulation on LPP pathogenesis, it is reasonable to suspect that the dyslipidemia caused by bexarotene may have triggered the onset of LPP in our patient. The patient’s lipid values mostly remained within reference range throughout the course of treatment, though she did have elevation of triglycerides around the onset of LPP. Dyslipidemia has been reported in patients with lichen planus but not in patients with LPP. One case-control study showed no dyslipidemia in patients with LPP, but the triglyceride levels were not tracked over time and patients had varying durations since onset of disease at presentation.9-11,13 In our case, we were fortunate to have this information, and it may suggest an interaction between lipid dysregulation and the development of LPP. It would be interesting to explore this further in a larger patient population and to evaluate if control of dyslipidemia reduces progression of disease as it appears to have done for our patient.

References
  1. Karp DL, Horn TD. Lymphomatoid papulosis. J Am Acad Dermatol. 1994;30:379-395; quiz 396-398.
  2. Krathen RA, Ward S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology. 2003;206:142-147.
  3. Targretin (bexarotene) capsule [package insert]. St. Petersburg, FL: Cardinal Health; 2003. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63656f64-e240-4855-8df9-ca1655863735. Accessed April 9, 2020.
  4. Assouly P, Reygagne P. Lichen planopilaris: update on diagnosis and treatment. Semin Cutan Med Surg. 2009;28:3-10.
  5. Dogra S, Sarangal R. What’s new in cicatricial alopecia? Indian J Dermatol Venereol Leprol. 2013;79:576-90.
  6. Zheng Y, Eilertsen KJ, Ge L, et al. Scd1 is expressed in sebaceous glands and is disrupted in the asebia mouse. Nat Genet. 1999;23:268-270.
  7. Sundberg JP, Boggess D, Sundberg BA, et al. Asebia-2J (Scd1(ab2J)): a new allele and a model for scarring alopecia. Am J Pathol. 2000;156:2067-2075.
  8. Karnik P, Tekeste Z, McCormick TS, et al. Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. J Invest Dermatol. 2009;129:1243-157.
  9. López-Jornet P, Camacho-Alonso F, Rodríguez-Martínes MA. Alterations in serum lipid profile patterns in oral lichen planus: a cross-sectional study. Am J Clin Dermatol. 2012;13:399-404.
  10. Arias-Santiago S, Buendía-Eisman A, Aneiros-Fernández J, et al. Lipid levels in patients with lichen planus: a case-control study. J Eur Acad Dermatol Venereol. 2011;25:1398-1401.
  11. Dreiher J, Shapiro J, Cohen AD. Lichen planus and dyslipidaemia: a case-control study. Br J Dermatol. 2009;161:626-629.
  12. de Vries-van der Weij J, de Haan W, Hu L, et al. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. Endocrinology. 2009;150:2368-2375.
  13. Conic RRZ, Piliang M, Bergfeld W, et al. Association of lichen planopilaris with dyslipidemia. JAMA Dermatol. 2018;154:1088-1089.
References
  1. Karp DL, Horn TD. Lymphomatoid papulosis. J Am Acad Dermatol. 1994;30:379-395; quiz 396-398.
  2. Krathen RA, Ward S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology. 2003;206:142-147.
  3. Targretin (bexarotene) capsule [package insert]. St. Petersburg, FL: Cardinal Health; 2003. http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63656f64-e240-4855-8df9-ca1655863735. Accessed April 9, 2020.
  4. Assouly P, Reygagne P. Lichen planopilaris: update on diagnosis and treatment. Semin Cutan Med Surg. 2009;28:3-10.
  5. Dogra S, Sarangal R. What’s new in cicatricial alopecia? Indian J Dermatol Venereol Leprol. 2013;79:576-90.
  6. Zheng Y, Eilertsen KJ, Ge L, et al. Scd1 is expressed in sebaceous glands and is disrupted in the asebia mouse. Nat Genet. 1999;23:268-270.
  7. Sundberg JP, Boggess D, Sundberg BA, et al. Asebia-2J (Scd1(ab2J)): a new allele and a model for scarring alopecia. Am J Pathol. 2000;156:2067-2075.
  8. Karnik P, Tekeste Z, McCormick TS, et al. Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. J Invest Dermatol. 2009;129:1243-157.
  9. López-Jornet P, Camacho-Alonso F, Rodríguez-Martínes MA. Alterations in serum lipid profile patterns in oral lichen planus: a cross-sectional study. Am J Clin Dermatol. 2012;13:399-404.
  10. Arias-Santiago S, Buendía-Eisman A, Aneiros-Fernández J, et al. Lipid levels in patients with lichen planus: a case-control study. J Eur Acad Dermatol Venereol. 2011;25:1398-1401.
  11. Dreiher J, Shapiro J, Cohen AD. Lichen planus and dyslipidaemia: a case-control study. Br J Dermatol. 2009;161:626-629.
  12. de Vries-van der Weij J, de Haan W, Hu L, et al. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. Endocrinology. 2009;150:2368-2375.
  13. Conic RRZ, Piliang M, Bergfeld W, et al. Association of lichen planopilaris with dyslipidemia. JAMA Dermatol. 2018;154:1088-1089.
Issue
Cutis - 105(4)
Issue
Cutis - 105(4)
Page Number
E19-E21
Page Number
E19-E21
Publications
Publications
Topics
Article Type
Display Headline
Lichen Planopilaris in a Patient Treated With Bexarotene for Lymphomatoid Papulosis
Display Headline
Lichen Planopilaris in a Patient Treated With Bexarotene for Lymphomatoid Papulosis
Sections
Inside the Article

Practice Points

  • Oral retinoids may be associated with development of lichen planopilaris (LPP).
  • Hypertriglyceridemia may be associated with onset of LPP.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Article PDF Media